Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review
The review gives the definition of HER2-low status, shows its clinical and biological role in patients with advanced breast cancer. A unique mechanism of action of trastuzumab deruxtecan and potential for its use in advanced breast cancer with HER2-low expression are described. The key results of th...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2023-10-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/1139 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399199799443456 |
|---|---|
| author | I. V. Kolyadina |
| author_facet | I. V. Kolyadina |
| author_sort | I. V. Kolyadina |
| collection | DOAJ |
| description | The review gives the definition of HER2-low status, shows its clinical and biological role in patients with advanced breast cancer. A unique mechanism of action of trastuzumab deruxtecan and potential for its use in advanced breast cancer with HER2-low expression are described. The key results of the open multicenter phase III DESTINY-Breast04 (DB-04) trial including safety data are presented. Results on the effectiveness of the drug in patients with markers of hormone resistance first presented in 2023 and the place of trastuzumab deruxtecan in the updated ESMO 2023 algorithm of hormone-positive breast cancer treatment are considered. |
| format | Article |
| id | doaj-art-d580ee40914b4a339c0abfeed76b9863 |
| institution | Kabale University |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| publishDate | 2023-10-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj-art-d580ee40914b4a339c0abfeed76b98632025-08-20T03:38:23ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272023-10-01193637610.17650/1994-4098-2023-19-3-63-76814Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies reviewI. V. Kolyadina0Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia; V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of RussiaThe review gives the definition of HER2-low status, shows its clinical and biological role in patients with advanced breast cancer. A unique mechanism of action of trastuzumab deruxtecan and potential for its use in advanced breast cancer with HER2-low expression are described. The key results of the open multicenter phase III DESTINY-Breast04 (DB-04) trial including safety data are presented. Results on the effectiveness of the drug in patients with markers of hormone resistance first presented in 2023 and the place of trastuzumab deruxtecan in the updated ESMO 2023 algorithm of hormone-positive breast cancer treatment are considered.https://ojrs.abvpress.ru/ojrs/article/view/1139breast cancer with her2-low expressiontrastuzumab deruxtecanmulticenter destiny-breast04 trialhormone resistanceesr1 mutationpiк3ca mutationer-low expressiontreatment algorithm for advanced breast cancer |
| spellingShingle | I. V. Kolyadina Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review Опухоли женской репродуктивной системы breast cancer with her2-low expression trastuzumab deruxtecan multicenter destiny-breast04 trial hormone resistance esr1 mutation piк3ca mutation er-low expression treatment algorithm for advanced breast cancer |
| title | Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review |
| title_full | Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review |
| title_fullStr | Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review |
| title_full_unstemmed | Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review |
| title_short | Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review |
| title_sort | trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with her2 low expression recent studies review |
| topic | breast cancer with her2-low expression trastuzumab deruxtecan multicenter destiny-breast04 trial hormone resistance esr1 mutation piк3ca mutation er-low expression treatment algorithm for advanced breast cancer |
| url | https://ojrs.abvpress.ru/ojrs/article/view/1139 |
| work_keys_str_mv | AT ivkolyadina trastuzumabderuxtecaninthetreatmentofpatientswithadvancedbreastcancerwithher2lowexpressionrecentstudiesreview |